BDBM224193 3-{7-[(trans-4- methylcyclohexyl) methyl]-6-[3-(5-methyl- 1,2,4-oxadiazol-3- yl)phenyl]-8-[(3r)-3- phenylmorpholin-4- yl]-7h-purin-2-yl}- 1,2,4-oxadiazol- 5(4h)-one::US9540377, 16.112

SMILES Cc1nc(-c2cccc(-c3nc(-c4noc(=O)[nH]4)nc4nc(N5CCOC[C@H]5c5ccccc5)n(C[C@H]5CC[C@H](C)CC5)c34)c2)no1

InChI Key InChIKey=UWSNFGZGXLHVQU-UHFFFAOYSA-N

Data  1 IC50

  Tab Delimited (TSV)   2D SDfile   Computed 3D by Vconf -m prep SDfile
Find this compound or compounds like it in BindingDB:
   Substructure
Similarity at least:  must be >=0.5
Exact match

Activity Spreadsheet -- Enzyme Inhibition Constant Data from BindingDB

Found 1 hit for monomerid = 224193   

TargetE3 ubiquitin-protein ligase Mdm2 [17-125](Human)
Merck Sharp & Dohme

US Patent
LigandChemical structure of BindingDB Monomer ID 224193BDBM224193(US9540377, 16.112 | 3-{7-[(trans-4- methylcyclohex...)
Affinity DataIC50: 18.1nMT: 2°CAssay Description:An HDM2 FRET assay was developed to assess the compounds' inhibitory activity towards binding of p53 protein. A truncated version of HDM2 with re...More data for this Ligand-Target Pair
In Depth
Date in BDB:
9/26/2018
Entry Details
US Patent